Meeting
2022 ASCO Genitourinary Cancers Symposium
Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).
Authors
Neeraj Agarwal
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Neeraj Agarwal , Arun Azad , Karim Fizazi , Joaquin Mateo , Nobuaki Matsubara , Neal D. Shore , Jayeta Chakrabarti , Hsiang-Chun Chen , Silvana Lanzalone , Alexander Niyazov , Fred Saad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04821622
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS221)
DOI
10.1200/JCO.2022.40.6_suppl.TPS221
Abstract #
TPS221
Poster Bd #
R3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).
First Author: Pedro C. Barata